<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335825</url>
  </required_header>
  <id_info>
    <org_study_id>1774</org_study_id>
    <nct_id>NCT04335825</nct_id>
  </id_info>
  <brief_title>Surgical and Refractive Outcomes of Combined Glaucoma Surgery</brief_title>
  <official_title>Surgical and Refractive Outcomes of Combined Phaco-ExPress Versus Phacotrabeculectomy - 6 Months Results.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine surgical and refractive outcomes of glaucoma combined&#xD;
      surgery in six months period of follow up&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trabeculectomy and implantation of the Ex-Press device belong to the same group of&#xD;
      anti-glaucoma procedures improving subconjunctival outflow. The most frequently performed&#xD;
      glaucoma surgery of choice is still trabeculectomy, although the less invasive implantation&#xD;
      of the Ex-Press device is also an effective alternative. Despite the wide application of&#xD;
      these two techniques, their impact on postoperative refraction is not entirely known. Quite&#xD;
      often, in the early postoperative period there is a decrease in visual function, which is&#xD;
      short-term, although there are reports that it can last up to a year after surgery. It can be&#xD;
      caused by a reduction in IOP, as well as the direct effect of trabeculectomy on corneal&#xD;
      topography, and thus on postoperative astigmatism and refractive error. The occurrence of&#xD;
      astigmatism after trabeculectomy has been widely documented Combined operations of implanting&#xD;
      the ExPress implant with cataract phacoemulsification differ from phacotrabeculectomy in&#xD;
      that, they do not require cutting of the sclera, cutting the limbus and using a punch.&#xD;
&#xD;
      The purpose of our research was to compare the phacotrabeculectomy and phacoemulsification&#xD;
      combined with Express device implantation in terms of incidence of postoperative astigmatism&#xD;
      in a prospective randomized study, and to attempt to determine what factors determine its&#xD;
      size.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IOP</measure>
    <time_frame>baseline and six months after surgery</time_frame>
    <description>the change in the level of intraocular pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>baseline and six months after surgery</time_frame>
    <description>the change in the best corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>astigmatism</measure>
    <time_frame>baseline and six months after surgery</time_frame>
    <description>the change in the value of astigmatism with the use of autokeratorefractometer before and after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <condition>Filtering Surgery</condition>
  <arm_group>
    <arm_group_label>phacotrabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients undergoing phacotrabeculectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ExPress device implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients undergoing ExPress antiglaucoma surgery combined with phacoemulsification</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phacotrabeculectomy</intervention_name>
    <description>combined antiglaucoma procedure: trabeculectomy with phacoemulsification</description>
    <arm_group_label>phacotrabeculectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ExPress antiglaucoma surgery combined with phacoemulsification</intervention_name>
    <description>combined antiglaucoma procedure: ExPress device implantation with phacoemulsification</description>
    <arm_group_label>ExPress device implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Glaucoma with coexisting cataract graded Nuclear-Cortical 1 (NC1) and Nuclear-Cortical&#xD;
             2 (NC2), according to the The Lens Opacities Classification System III (LOCS III&#xD;
             scale), was an indication for surgery.&#xD;
&#xD;
          -  Patients with primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PXG) and&#xD;
             pigmentary glaucoma (PG), in which satisfactory intraocular pressure (IOP &gt;21 mmHg)&#xD;
             was not achieved despite maximally-tolerated topical and systemic medication, were&#xD;
             qualified for treatment.&#xD;
&#xD;
          -  Additional inclusion criteria were as follows: well documented progression of visual&#xD;
             field defects, significant diurnal variations in the IOP, poor patient compliance, and&#xD;
             allergy to topical drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of consent to participate in the study,&#xD;
&#xD;
          -  History of eye surgery or laser procedures within the eye,&#xD;
&#xD;
          -  Closed or narrow angle glaucoma,&#xD;
&#xD;
          -  Diabetes,&#xD;
&#xD;
          -  Advanced macular degeneration&#xD;
&#xD;
          -  Active inflammatory disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Chan HHL, Kong YXG. Glaucoma surgery and induced astigmatism: a systematic review. Eye Vis (Lond). 2017 Nov 17;4:27. doi: 10.1186/s40662-017-0090-x. eCollection 2017. Review.</citation>
    <PMID>29177182</PMID>
  </results_reference>
  <results_reference>
    <citation>Hong YJ, Choe CM, Lee YG, Chung HS, Kim HK. The effect of mitomycin-C on postoperative corneal astigmatism in trabeculectomy and a triple procedure. Ophthalmic Surg Lasers. 1998 Jun;29(6):484-9.</citation>
    <PMID>9640570</PMID>
  </results_reference>
  <results_reference>
    <citation>Alvani A, Pakravan M, Esfandiari H, Safi S, Yaseri M, Pakravan P. Ocular Biometric Changes after Trabeculectomy. J Ophthalmic Vis Res. 2016 Jul-Sep;11(3):296-303. doi: 10.4103/2008-322X.188399. Review.</citation>
    <PMID>27621788</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma combined surgery</keyword>
  <keyword>postoperative astigmatism</keyword>
  <keyword>postsurgery refractive error</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data of each participant will be available upon email request for all primary and secondary outcome measures</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available on email request for six months after completing the study</ipd_time_frame>
    <ipd_access_criteria>e mail request, after Data Access Agreement is sign</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

